Skip to main content
ARROWHEAD PHARMACEUTICALS, INC. logo

ARROWHEAD PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · ARWR ISIN · US04280A1007 LEI · 549300O3CSB8T7OZ3D66 US Manufacturing
Open in API
Filings indexed 1,039 across all filing types
Latest filing 2009-06-29 Regulatory Filings
Country US United States of America
Listing US ARWR

About ARROWHEAD PHARMACEUTICALS, INC.

https://arrowheadpharma.com/

Arrowhead Pharmaceuticals, Inc. is a biotechnology company that develops medicines to treat intractable diseases by silencing the genes that cause them. The company utilizes its proprietary RNA interference (RNAi) platform to create therapies that target disease pathways previously considered 'undruggable.' Arrowhead's development pipeline is focused on a broad range of therapeutic areas, including cardiometabolic, pulmonary, neuromuscular, and liver diseases. The company advances a portfolio of clinical-stage candidates designed to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes detailed descriptions of material definitive agreements, license agreements, equity transactions, and other corporate events. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or quarterly reports. It also does not fit into categories like earnings release, proxy statements, or management reports. The primary purpose is to disclose significant corporate events and transactions. Therefore, the document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2009-06-29 English
Regulatory Filings 2009
Regulatory Filings
2009-06-25 English
FORM 8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated May 20, 2009, by Arrowhead Research Corporation. The content focuses on a notice of delisting or failure to satisfy a continued listing rule due to non-compliance with NASDAQ's minimum stockholders' equity requirement. It includes a reference to a press release about the delisting issue. The document is short (2918 characters) and primarily serves as an announcement of the delisting event and related communications, not a full financial report or detailed analysis. According to the filing definitions and rules, this fits the category of a Delisting Announcement (DLST).
2009-05-27 English
FORM 10-Q
Interim / Quarterly Report Q2 2009
2009-05-15 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated May 13, 2009. It announces a joint development agreement between a subsidiary and LG Display, and includes a news release as an exhibit. The content is a regulatory announcement of a corporate event rather than a financial report, earnings release, or management discussion. The document length is short (2416 characters), and it primarily serves as a regulatory filing to disclose material information promptly. Therefore, it fits best under Regulatory Filings (RNS) as a general SEC announcement that does not fit other specific categories.
2009-05-13 English
DOC ONE
Major Shareholding Notification
2009-05-11 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.